JBC Ideal method for primary cell transfection

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zrihan-Licht, S.
Right arrow Articles by Avraham, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zrihan-Licht, S.
Right arrow Articles by Avraham, H.

J Biol Chem, Vol. 273, Issue 7, 4065-4072, February 13, 1998

Csk Homologous Kinase, a Novel Signaling Molecule, Directly Associates with the Activated ErbB-2 Receptor in Breast Cancer Cells and Inhibits Their Proliferation

Sheila Zrihan-Licht, Bijia Deng, Yosef YardenDagger , Gina McShan, Iafa Keydar§, and Hava Avraham

From the Divisions of Experimental Medicine and Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, Boston, Massachusetts 02115, the Dagger  Department of Chemical Immunology, the Weizmann Institute of Science, Rehovot 76100, Israel, and the § Department of Cell Research and Immunology, Tel Aviv University, Ramat Aviv 69978, Israel

Substantial evidence exists supporting direct roles for ErbB-2/neu and Src kinase activation in breast cancer. The Csk homologous kinase (CHK) is a recently identified tyrosine kinase which, like Csk, phosphorylates the C-terminal tyrosine of Src kinases, resulting in inactivation of these enzymes. Recently, we observed that CHK is associated with the ErbB-2/neu receptor upon heregulin stimulation of breast cancer cells. Here, we report that CHK expression was observed in 70 out of 80 primary breast cancer specimens but not in normal breast tissues (0/19). Confocal microscopy analysis revealed co-localization of CHK with ErbB-2 in these primary specimens (6/6). In addition, we observed that the cytoplasmic domain of the ErbB-2/neu receptor is sufficient for its interaction with the CHKSH2 domain. Phosphopeptide inhibition of the in vitro interaction of CHKSH2 or native CHK with ErbB-2/neu, as well as site-directed mutagenesis of ErbB-2/neu, indicated that CHKSH2 binds to Tyr1253 of ErbB-2/neu. Interestingly, autophosphorylation at this site confers oncogenicity to this receptor. Moreover, CHK was able to down-regulate ErbB-2/neu-activated Src kinases. Overexpression of CHK in MCF-7 breast cancer cells markedly inhibited cell growth and proliferative response to heregulin as well as decreased colony formation in soft agar. These studies indicate that CHK binds, via its SH2 domain, to Tyr1253 of the activated ErbB-2/neu and down-regulates the ErbB-2/neu-mediated activation of Src kinases, thereby inhibiting breast cancer cell growth. These data strongly suggest that CHK is a novel negative growth regulator in human breast cancer.

Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
R. Kaminski, R. Zagozdzon, Y. Fu, P. Mroz, W. Fu, S. Seng, S. Avraham, and H. K. Avraham
Role of Src Kinases in Neu-Induced Tumorigenesis: Challenging the Paradigm Using Csk Homologous Kinase Transgenic Mice
Cancer Res., June 1, 2006; 66(11): 5757 - 5762.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. K. Ayrapetov, N. H. Nam, G. Ye, A. Kumar, K. Parang, and G. Sun
Functional Diversity of Csk, Chk, and Src SH2 Domains due to a Single Residue Variation
J. Biol. Chem., July 8, 2005; 280(27): 25780 - 25787.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B.-C. Lee, T.-H. Lee, R. Zagozdzon, S. Avraham, A. Usheva, and H. K. Avraham
Carboxyl-Terminal Src Kinase Homologous Kinase Negatively Regulates the Chemokine Receptor CXCR4 through YY1 and Impairs CXCR4/CXCL12 (SDF-1{alpha})-Mediated Breast Cancer Cell Migration
Cancer Res., April 1, 2005; 65(7): 2840 - 2845.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
Y. Li, W.-h. Yu, J. Ren, W. Chen, L. Huang, S. Kharbanda, M. Loda, and D. Kufe
Heregulin Targets {gamma}-Catenin to the Nucleolus by a Mechanism Dependent on the DF3/MUC1 Oncoprotein
Mol. Cancer Res., August 1, 2003; 1(10): 765 - 775.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Kim, R. Zagozdzon, A. Meisler, J. D. Baleja, Y. Fu, S. Avraham, and H. Avraham
Csk Homologous Kinase (CHK) and ErbB-2 Interactions Are Directly Coupled with CHK Negative Growth Regulatory Function in Breast Cancer
J. Biol. Chem., September 20, 2002; 277(39): 36465 - 36470.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Yamashita, S. Avraham, S. Jiang, I. Dikic, and H. Avraham
The Csk Homologous Kinase Associates with TrkA Receptors and Is Involved in Neurite Outgrowth of PC12 Cells
J. Biol. Chem., May 21, 1999; 274(21): 15059 - 15065.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Bougeret, S. Jiang, I. Keydar, and H. Avraham
Functional Analysis of Csk and CHK Kinases in Breast Cancer Cells
J. Biol. Chem., August 31, 2001; 276(36): 33711 - 33720.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.